leadf
logo-loader
RNS
viewMotif Bio PLC

Motif Bio PLC - Result of AGM

RNS Number : 6378A
Motif Bio PLC
30 September 2020
 

 

 

Motif Bio plc

 

("Motif Bio" or the "Company")

 

Result of AGM

 

Motif Bio plc (AIM: MTFB) announces that at the Annual General Meeting of the Company held earlier today at the offices of ONE Advisory Limited, 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT all but one of the resolutions put to members were passed on a poll.

 

The Board notes that resolution 7, which was proposed as a special resolution regarding the disapplication of pre-emption rights, was not passed.

 

The number of votes lodged by proxy and voted on by poll for and against each of the resolutions proposed, and the number of votes withheld, were as follows:

 

Resolution

FOR*

%

AGAINST

%

WITHHELD

Resolution 1 (Ordinary)

To receive the Company's annual accounts and the strategic, directors' and auditors' reports for the year ended 31 December 2019.

 

37,371,686

 

91.94

 

 

3,275,355

 

8.06

 

 

131,590

Resolution 2 (Ordinary)

To re-elect Graham Lumsden as a Director of the Company

 

27, 167,596

 

66.74

 

 

13,541,866

 

33.26

 

 

69,169

Resolution 3 (Ordinary)

To re-elect Christopher Wardhaugh as a director of the Company, who was appointed by the board since the last annual general meeting.

 

 

34,740,854

 

 

85.42

 

 

 

5,930,684

 

 

14.58

 

 

 

107,093

Resolution 4 (Ordinary)

To re-appoint the Company's auditor Crowe LLP, who have been appointed by the board since the last annual general meeting.

 

 

37,286,396

 

 

91.56

 

 

 

 

3,437,066

 

 

8.44

 

 

 

55,169

Resolution 5 (Ordinary)

That the Directors be authorised to fix the auditors remuneration.

 

36,844,682

 

 

90.71

 

 

 

3,772,431

 

9.29

 

 

161,518

Resolution 6 (Ordinary)

To empower the directors to allot relevant securities pursuant to Section 551 of the Act

 

33,534,192

 

84.95

 

 

5,941,430

 

 

15.05

 

 

1,303,009

Resolution 7 (Special)

To disapply the pre-emptive rights contained in Section 561 of the Act

 

26,246,162

 

73.09

 

 

 

9,844,855

 

26.91

 

 

4,187,614

 

 

 

*including votes granting discretion to the chair

 

As at 30 September 2020, there were 654,991,023 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

Motif Bio plc

 

[email protected]

Jonathan Gold (President and Chief Business Officer)

 

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

 

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

[email protected]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBXGDCXDXDGGG

Quick facts: Motif Bio PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read